New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
09:03 EDTINOInovio repsonds to third party article regarding immunotherapy study
Inovio announced that it wishes to clarify that a third party article published on June 10, was misrepresentative of facts and can only be taken as malicious. The company said the referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading conjecture. Inovio has indicated that it expects to report mid-year the top-line results of its phase II clinical trial evaluating VGX-3100 for the treatment of cervical dysplasia. Inovio said it designed the double blind, placebo controlled phase II study to comprehensively measure efficacy, HPV viral clearance, immunogenicity, and safety. At this time the data remains blinded and the company aims to report this data by the end of July. Inovio adds, "We are hopeful that these results could lead to a novel therapeutic option for women to avoid the invasive current surgical procedure. There exists the prospect that our immunotherapy approach may eliminate the presence of HPV virus to minimize future recurrences."
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
11:22 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 29, 2014
11:46 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI ANGI MLNX INFN TTS QLIK DECK SKX CRUS
July 28, 2014
11:18 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 25, 2014
11:08 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI MLNX DECK INFN CMG QLIK LKX ANGI NFLX
July 24, 2014
11:15 EDTINOInovio upgraded to Buy from Hold at Aegis
Aegis upgraded Inovio to Buy following positive top-line data from the clinical trial of its lead human papillomavirus DNA-based vaccine, VGX-3100, in patients with high-grade cervical dysplasia. Price target raised to $19 from $10.
10:26 EDTINOOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2014
16:47 EDTINOInovio files $175M mixed securities shelf
13:21 EDTINOInovio says ITT analysis achieved statistical significance in VGX-3100 trial
Subscribe for More Information
11:21 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
11:08 EDTINOHigh option volume stocks
Subscribe for More Information
09:44 EDTINOInovio price target raised to $29 from $26 at Piper Jaffray
Subscribe for More Information
09:20 EDTINOInovio's VGX-3100 for cervical dysplasia shows positive Phase II results
Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.
July 21, 2014
07:11 EDTINOInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use